REPLY
23.3.2023 09:01:30 CET | Business Wire | Press release
The digital asset market is growing exponentially. Thanks to blockchain technology and the new generation of operators using tokenization platforms, it is possible to turn everything that can be digitally archived into a digital asset, with recognised value and established ownership. This is what emerges from Reply's new ‘Digital Assets Trends’ research, based on the Reply SONAR platform. By analysing industry studies, scientific articles, patents, documents, and B2B content published in the last year, and integrating concrete experiences from Reply's clients, the study examines the main trends related to digital assets.
Tokenization is the first step to bringing real-world assets and financial instruments onto the blockchain, representing an opportunity especially for those of an illiquid nature (e.g., high-value art, public infrastructure, private equity). The main advantages of tokens include the construction of a peer-to-peer network without intermediaries that also serves as a decentralised network, end-to-end traceability with the possibility of proving ownership at any time, and automated record-keeping that simplifies every aspect of compliance.
"Digital assets still constitute less than 1% of the global financial system, but they have already grown exponentially and will continue this trend in the years to come," commented Filippo Rizzante, CTO of Reply. "Today, Reply is already supporting the demands of various financial institutions, as well as some major players in healthcare, energy, fashion, and public administration, in the adoption of digital assets enabled by a growing maturity of the regulatory framework and the intense work of central banks on their digital currencies."
The study essentially identifies 4 macro-categories of emerging digital assets, these are: payment tokens, non-fungible tokens (NFTs), utility tokens, and security tokens.
Payment tokens include cryptocurrencies and stablecoins. These currencies have not yet been issued by governments or other financial institutions, but are monitored and organised on a decentralised network. This network also serves as a secure ledger for each transaction, pending the first regulations that will come into force in 2024. The rapid and increased circulation of this type of asset has pushed central banks to explore their digital currencies, namely the Central Bank Digital Currencies, and the ECB has also started developing pilot projects for a digital Euro.
Non-fungible tokens are a digital representation of real assets or natively digital assets to be collected or used in virtual worlds. NFTs find application in various sectors, including asset management and the art market. Currently, they are not subject to any regulation and find the greatest potential within the metaverse.
Utility tokens allow the user to perform an action on a specific blockchain or decentralised application. They have been particularly popular for so-called initial coin offerings (ICOs), but today they are mainly used to redeem services and digital products in predefined ecosystems, such as those of cloud or online gaming.
Security tokens are a digital representation of a traditional financial instrument (stocks, bonds and derivatives). As digital assets, they offer additional benefits, including greater flexibility in the creation and distribution process for SMEs and startups. In addition to the existing security tokens that the European Investment Bank launched, the Reply SONAR platform has identified a growing interest in the tokenization of carbon credits, which concern a typically opaque and inefficient market like blockchain technology. This could revolutionise the monetary side of the life cycle of a tokenized carbon offset by tokenizing the credits.
The ‘Digital Assets Trends’ research can be downloaded here.
This study is part of the ‘Reply Trend SONAR’ series, which includes ‘Digital Experience Trends 2023’, ‘Metaverse: the potential beyond the hype’, and ‘Sustainability Trends’.
Reply
Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230323005053/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
